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Abstract 
A nonheme Fe(II) complex (1) that models substrate-bound cysteine dioxygenase (CDO) reacts with O2 at −80 °C to 
yield a purple intermediate (2). Analysis with spectroscopic and computational methods determined that 2 features a 
thiolate-ligated Fe(III) center bound to a superoxide radical, mimicking the putative structure of a key CDO 
intermediate. 
 
The metabolism of amino acids and related biomolecules is often dependent upon mononuclear nonheme 
iron enzymes (NHIEs) that activate O2 for the oxidation of organic substrates.1 An example with significance for human 
health is cysteine dioxygenase (CDO), a NHIE that transforms exogenous L-cysteine (Cys) into cysteine sulfinic acid (Cys-
SO2H) in an O2-dependent process.2 This reaction is the first step in the eventual conversion of Cys to either taurine or 
sulfate.3 A thiol dioxygenation reaction is also catalyzed by cysteamine dioxygenase (ADO) in the degradation pathway 
of coenzyme A.4 CDO and ADO activities are essential for avoiding elevated cellular levels of free thiols, which have 
been linked to neurological conditions5 and autoimmune disorders.6 The active site of CDO consists of an Fe(II) center 
facially coordinated by three histidine residues.7 X-ray studies revealed that the deprotonated Cys substrate binds to 
the Fe(II) center in a bidentate N,S-mode (Scheme 1),8 and a similar substrate-bound geometry is likely adopted by 
ADO.  
 
Scheme 1 Proposed CDO mechanism (RDS = rate-determining step). 
In the proposed mechanism, the sequential binding of thiolate and O2 yields a six-coordinate iron(III)–
superoxide adduct.9 As required of iron enzymes that catalyze four-electron substrate oxidations,10 the iron(III)–
superoxo species of CDO/ADO initiates oxidation of the coordinated substrate, in this case through generation of a 
putative FeII–O–O–S intermediate (Scheme 1). DFT studies suggest that formation of this cyclic peroxo intermediate is 
the rate-determining step in the catalytic cycle.11 Thus, the iron(III)–superoxo species occupies the pivotal position in 
the catalytic mechanisms of thiol dioxygenases. Yet it has proven difficult to detect this intermediate in studies of CDO 
and related model complexes. Nonheme iron–superoxo species exhibit short lifetimes even at reduced temperatures, 
and their EPR-silent nature and lack of distinct absorption features hinder spectroscopic characterization. Due to these 
factors, only four synthetic nonheme iron–superoxo complexes have been reported thus far (three mononuclear and 
one dinuclear).12 
Recently, we described the synthesis and reactivity of CDO and ADO models that employed a tris(imidazol-2-
yl)phosphine ligand to mimic the 3-histidine triad.13 Although exposure of these functional models to O2 yields the 
corresponding sulfinic acid products, intermediates of the dioxygenation reaction were not detected. Since then, we 
surmised that it might be possible to extend the lifetime of reactive species by preparing CDO models with alternative 
substrates that are similar to, but not identical with, the native substrate. Moreover, our experience with cobalt-
substituted CDO models,14 as well as a report from the Hikichi group,12b suggested that the hydrotris(3,5-
dimethylpyrazolyl)borate ligand (TpMe2) facilitates formation of metal–superoxo species due to its small steric profile. 
With these ideas in mind, we prepared the complex, [Fe(TpMe2)(2-ATP)] (1), where 2-ATP is 2-aminothiophenolate (Fig. 
1). The monoanionic 2-ATP ligand was selected based on biochemical studies by Pierce and coworkers that suggest it 
binds to the Fe(III) center of CDO in a manner analogous to Cys.15 Here we describe the O2 reactivity of complex 1and 
provide spectroscopic evidence for the formation of a mononuclear iron–superoxo intermediate at low temperature. 
 
Fig. 1 Schematic drawing (left) and X-ray crystal structure (right) of [Fe(TpMe2)(2-ATP)] (1). Selected bond distances (Å) and an    
2.3107(4), Fe1–N2 2.0746(12), Fe1–N4 2.0817(12), Fe1–N6 2.1843(12), Fe1–N7 2.2776(13), S1–Fe1–N2 121.83(4), S1–Fe1–N    
171.75(4). 
Complex 1 is generated by treatment of an iron(II) acetate precursor, [FeII(TpMe2)(OAc)], with the sodium salt of 
2-ATP in CH3CN. The complex can also be prepared, albeit in lower yield, by direct reaction of equimolar amounts of 
Fe(OTf)2, K(TpMe2), 2-aminothiophenol, and NaOMe. The UV-vis absorption spectrum of 1 in THF exhibits two weak 
features at 560 and 920 nm with molar absorptivities (εM) near 100 M−1 cm−1 (Fig. 2). Light yellow crystals suitable for 
crystallographic analysis were grown by slow evaporation of solvent. The resulting X-ray structure, shown in Fig. 1, 
reveals a mononuclear, five-coordinate Fe(II) complex that lies midway between idealized square pyramidal and 
trigonal bipyramidal geometries (τ-value of 0.52). The average Fe–NTp bond length of 2.11 Å is typical of high-spin Fe(II) 
complexes with TpMe2 ligands, and the Fe–S bond length of 2.31 Å is virtually identical to values observed for CDO 
models with aliphatic thiolates.13,16 
 
 
Fig. 2 Electronic absorption spectra of 1, 2, and 3 (0.84 mM) in THF at −80 °C. 
 
Exposure of complex 1 to O2 at low temperature (−80 °C) generates a purple chromophore (2) that features 
three absorption bands at 490 (εM = 1200), 655 (1800), and 860 nm (2200), as shown in Fig. 2. This EPR-silent 
intermediate decays at −80 °C with a half-life of 10 minutes, eventually yielding a greenish EPR-active species (3) with a 
broad absorption band centered at 830 nm (the EPR data are shown in Fig. S1, ESI†). The reaction with O2 is 
irreversible, as bubbling argon gas through the solution at −80 °C fails to regenerate 1. Species 2 is not observed when 
the O2 reaction is performed at room temperature; instead, complex 1 converts directly to 3. A survey of solvents 
determined that 2 is only generated in THF and 2-methyltetrahydrofuran (MeTHF). The glassy nature of frozen MeTHF 
made it possible to examine 2 with magnetic circular dichroism (MCD) spectroscopy at low temperatures (4–25 K). The 
MCD bands, which correspond to those observed in the absorption spectrum, display temperature-dependent 
intensities arising from C-term behavior (Fig. S2, ESI†), which confirms that 2 is a paramagnetic species. Furthermore, 
variable-temperature variable-field MCD data collected at 885 nm provided a set of “nested” magnetization curves 
(Fig. S3, ESI†) characteristic of a species with S ≥ 1.17 
Resonance Raman (rR) spectra of intermediate 2 were collected in multiple solvents (THF, THF-d8, and MeTHF) 
using 501.7 nm laser excitation. As shown in Fig. 3a, the spectra of 2 in THF and THF-d8 exhibit peaks at 1105 and 1135 
cm−1, respectively, that are absent in samples prepared with 18O2. We also examined samples prepared by either 
exposing 1 to O2 at room temperature or warming/refreezing samples of 2. The resulting rR spectra are devoid of non-
solvent features in the relevant region (Fig. S4, ESI†), proving that the observed vibrations arise from 2 and not a decay 
product like 3. As summarized in Table 1, frequencies between 1100 and 1200 cm−1 are typical of ν(O–O) modes of η1-
superoxo ligands in nonheme iron complexes. While the presence of two ν(O–O) vibrations could be indicative of 
multiple species, it is more likely that the 1105/1135 cm−1 pair correspond to a Fermi doublet centered near 1120 cm−1. 
Indeed, a Fermi doublet with a peak separation of ∼30 cm−1 was also observed for the ν(16O–16O) mode of the TpMe2-
based iron(III)–superoxo complex generated by Hikichi.12b Based on literature values (Table 1), the 
corresponding ν(18O–18O) mode of 2 is expected to appear between 1040 and 1070 cm−1. This region is largely 
obscured by solvent peaks in THF and THF-d8; however, an isotope-sensitive peak is observed at 1055 cm−1 in MeTHF 
(Fig. 3b). Assignment of this peak to the ν(18O–18O) mode provides an 16O2/18O2 downshift (Δ18O) of 65 cm−1, nearly 
identical to the value predicted by Hooke's law. 
 
 Fig. 3 rR spectra of 2 prepared with 16O2 (black lines) or 18O2 (red lines). Spectra were collected in either THF (a, top), THF-d8 (      
and c) using 501.7 nm laser excitation (40 mW). Frequencies (in cm−1) are provided for selected peaks, with the 16O2/18O2 isot     
parenthesis in part (c). Peaks marked with an asterisk (*) are due to solvent. As the ν(O–O) peaks are weak compared to the   
the spectrum of 1 in frozen MeTHF is also shown (blue lines) in part (b). 
 
Table 1 Frequencies and isotope shifts (in cm−1) reported for mononuclear iron and cobalt complexes with end-on (η1) 
superoxo ligandsa 
Complex ν(O–O) Δ(18O) ν(M–O) Δ(18O) Ref. 
[Fe(O2)(TpMe2)(2-ATP)] (2) 1120b 65 504 16 This work 
[Fe(O2)(TpMe2)(LPh)] 1168b 78 592 24 12b 
[Fe(O2)(BDPP)] 1125 63 n.r. n.r. 12a 
Oxy Cyt P450cam 1139 66 541 30 20 
[Co(O2)(TpMe2)(LPh)] 1150 60 543 21 12b 
[Co(O2)(BDPP)] 1135 65 n.r. n.r. 21 
[Co(O2)(py)(salen)] 1144 62 527 16 22 
[Co(O2)(TpMe2)(CysOEt)] 1152 61 n.r. n.r. 14 
a n.r. = not reported. b Average frequency of Fermi doublet peaks. 
 
In contrast to the ν(O–O) peaks, which are very weak for all nonheme iron(III)–superoxo species reported to 
date,12a,b the isotope-sensitive rR features in the low-frequency region of 2 are fairly intense (Fig. 3c). Analysis of these 
peaks further supports the proposition that 2 is an iron–superoxo species. The dominant peak at 504 cm−1 lies within 
the range of 470–595 cm−1 reported for ν(Fe–O) frequencies of heme and nonheme iron–superoxo 
complexes.12b,18 Although the measured Δ18O downshift of 16 cm−1is smaller than the value of 22 cm−1 predicted for a 
pure ν(Fe–O) mode, it is similar to shifts reported for related species (Table 1). A handful of weaker peaks in this region 
exhibit small Δ18O-values (<10 cm−1), which suggests that ν(Fe–O) character is distributed across multiple modes due to 
coupling. The lower-frequency peaks at 324 (Δ18O = 9 cm−1) and 352 cm−1 (Δ18O = 2 cm−1) are attributed to δ(Fe–O–O) 
and ν(Fe–S) modes, respectively, based on the magnitudes of the isotope shifts and literature precedents.12b,18a,19 
Further insights into the geometric and electronic structures of 2 were gained through density functional 
theory (DFT) calculations that employed the B3LYP functional, which has proven accurate in previous studies of CDO 
and related model complexes.11,23 Due to exchange interactions between the unpaired electrons of Fe and O2, it was 
necessary to consider three possible spin states for this paramagnetic iron(III)–superoxo species: S = 3, 2, and 1. The 
relative energies of the computational models suggest that 2 possesses a S = 2 ground state arising from 
antiferromangetic coupling between the high-spin Fe(III) center and superoxide radical (details regarding the spin-state 
ordering are provided in the ESI†). In the lowest-energy quintet structure (Fig. 4), the superoxo ligand forms a 
hydrogen bond with the –NH2 donor of 2-ATP, as evident in the O⋯H distance of 1.81 Å and diminished Fe–O–O angle 
of 122° (versus 134° in the structure without a H-bond). The H-bond acts as a tether between the superoxo and 2-ATP 




Fig. 4 DFT geometry-optimized model of 2 in the quintet (S = 2) state. Interatomic distances (black text) are provided in Å, an    
populations (green text) are indicated for atoms carrying significant spin density. 
 
In support of the veracity of our computational model, time-dependent DFT (TD-DFT) studies of 2 in the 
quintet state yielded a computed absorption spectrum that nicely reproduces the salient features of the experimental 
spectrum (Fig. S5, ESI†). The TD-DFT results were also helpful for assigning the experimental absorption bands. Like 
previously-reported ferric η1-superoxo complexes, 2 exhibits an intense near-UV band paired with a weaker shoulder in 
the visible region; however, the peaks observed at 655 and 860 nm lack precedent in the earlier complexes with N5 or 
N3O2 supporting ligands.12a,12b TD-DFT calculations indicate that these lower-energy bands are largely due to two 
moderately intense Sπ → Fe(III) charge transfer (CT) transitions (λmax = 669 and 833 nm for the computed transitions; 
Fig. S5, ESI†). The experimental feature at 500 nm is attributed by TD-DFT to overlapping Sσ → Fe(III) and O2˙− → Fe(III) 
CT transitions (the Sπ and Sσ orbitals lie perpendicular and parallel to the Fe–S axis, respectively). The near-UV peak has 
primarily O2˙− → Fe(III) CT character. 
The products generated by reaction of 1 with O2 were isolated from oxygenated THF solutions, followed by 
analysis with 1H NMR spectroscopy. These studies revealed that the sole product derived from the 2-ATP ligand is 2-
aminophenyl disulfide, as confirmed by comparison to spectra measured with authentic compound (Fig. S6, ESI†). The 
absence of observable S-oxygenated products, such as sulfinic or sulfonic acids, suggests that the decay of the iron–
superoxo species 2 does not proceed via formation of a S–O bond. Interestingly, Pierce and coworkers recently 
demonstrated that CDO, like 1, does not perform the S-dioxygenation of 2-aminothiophenol; instead, it converts this 
substrate to a benzothiazole compound via oxidative condensation with a primary alcohol.15 
The lack of sulfur oxygenation is due to an alternative pathway that combines dissociation of superoxide with 
deprotonation of the 2-ATP ligand, yielding an iron(III)-amidothiophenolate species as the ultimate product. This 
scenario is consistent with the O2reactivity of related Fe(II) catecholate and o-aminophenolate complexes, which have 
been shown to undergo one-electron oxidation and loss of a proton (from the –OH or –NH2 donor) upon exposure to 
O2 at room temperature.24 In support of this conclusion, the optical and EPR features of complex 3 closely resemble 
those reported by Paine et al. for ferric o-amidophenolate complexes.24a This decay pathway is the most viable option 
for 2 because the aromatic ring increases the acidity of the –NH2donor of 2-ATP relative to aliphatic amines, such as 
Cys. In fact, our DFT studies suggest that the energetic barrier for proton transfer from 2-ATP to superoxide is lower 
than the barrier for formation of a S–O bond by nearly 4 kcal mol−1 along the S = 2 surface. Further decay of 3 yields the 
observed disulfide product. 
To summarize, species 2 represents first report of a synthetic mononuclear iron–superoxo complex featuring a 
sulfur-based ligand, and the first example with direct relevance to a particular NHIE active site. We anticipate that our 
findings will assist in the identification of catalytic intermediates in related enzymes. To this point, Jameson et 
al. recently observed a short-lived species in the CDO catalytic cycle that exhibits two equally-intense CT bands at 500 
and 640 nm.11b The authors concluded that these features arise from either an iron–superoxo or Fe–O–O–S 
intermediate (Scheme 1), with the latter possibility favoured by TD-DFT calculations. While the two Sπ → Fe CT bands 
of 2 are red-shifted by ∼4500 cm−1 relative to the observed CDO bands, the overall similarity between the two spectra 
suggests that the CDO intermediate is an iron–superoxo species. This conclusion is further supported by a recent study 
of isopenicillin N synthase (IPNS) – another NHIE with iron-thiolate coordination – that detected an iron–superoxo 
intermediate with two absorption bands at 500 and 630 nm.25 Thus, the presence of two CT bands at λmax ≥ 500 nm 
appears to be a general feature of thiolate-coordinated nonheme iron–superoxo species in both synthetic and 
enzymatic environments. Studies of the reactivity of 2 towards various substrates, as well as the synthesis of iron–
superoxo complexes related to other NHIEs, are in progress. 
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